Jewim Pharmaceutical (Shandong) Co., Ltd

C26H26N4O5, triclinic, P1‾$\overline{1}$ (no. 2), a = 7.245(2) Å, b = 12.522(3) Å, c = 13.789(3) Å, α = 75.420(1)°, β = 79.628(1)°, γ = 83.226(1)°, V = 1,187.5(5) Å3, Z = 2, Rgt(F) = 0.0467, wRref(F2) = 0.1399, T = 298 K.

C9H11NO2, monoclinic, P21/c (no. 14), a = 11.293(4) Å, b = 6.998(3) Å, c = 10.932(4) Å, β = 104.175(7)°, V = 837.6(5) Å3, Z = 4, Rgt(F) = 0.0578, wRref(F2) = 0.1330, T = 296 K.

Objective To prepare single crystal of vortioxetine DL-lactate, and investigate the structure characterization.Methods Evaporation method was used to grow single crystals of vortioxetine DL-lactate, which were then characterized using thermal gravimetric analyzer(TGA), differential scanning calorimetry(DSC), Fourier transform IR spectrometer(IR), powder X-ray diffraction(PXRD), and single X-ray diffraction(SXRD).Results Single colorless block crystal of vortioxetine DL-lactate form βcould be obtained through acetonitrile evaporationDSC graph and PXRD spectrum was in good agreement with data reported in literatures.SXRD results showed that the unit stoichiometric of vortioxetine DL-lactate was C21 H28 N2 O3 S, and the relative mol. mass was 388.51, and crystal d. was 1.246 g/cm3.The unit cell belonged to a monoclinic system, and the space group was P21/c.Conclusion Crystal structure of vortioxetine DL-lactate is characterized by single X-ray diffraction, which provides a basis for the further development of vortioxetine DL-lactate.